Merck KGaA, Darmstadt, Germany: Carcinoma trials

The registry lists 16 Carcinoma studies with Merck KGaA, Darmstadt, Germany as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 3Phase 2 6Phase 3 3No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)CompletedNCT05650164Results posted
• A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has SpreadCompletedNCT05431777Results posted
• Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck CancerCompletedNCT02383966Phase 3Results posted
• Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)CompletedNCT02155647Phase 2Results posted
• c-Met Second-Line Hepatocellular CarcinomaCompletedNCT02115373Phase 1/2Results posted
• Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Phase 1/2Results posted
• A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and NeckCompletedNCT01177956Phase 3Results posted
• EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT01040832Phase 2Results posted
• Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese SubjectsCompletedNCT01012258Phase 3Results posted
• Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)CompletedNCT00971932Phase 2Results posted
• Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)WithdrawnNCT06424717Phase 2
• Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)Approved for marketingNCT03089658
• EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and NeckTerminatedNCT01360827Phase 1
• A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckTerminatedNCT01303237
• An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and NeckTerminatedNCT01142869
• A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)CompletedNCT01080066